Chemodenervation (April 2001)

Why This Topic Matters

Chemodenervation procedures are reported in specific CPT categories, and the article helps readers identify what changed in the 2001 update and how the topic fits into broader CPT reporting. It also places the procedure in a clinical context that can affect documentation review and code selection.

Article Sections

1. CPT 2001 overview

   Introduces the 2001 CPT update related to chemodenervation and the relevant section structure. Summarizes the editorial context for the topic.

2. Why Is Chemodenervation Effective?

   Explains the physiologic basis of chemodenervation and the general way botulinum toxin acts at the neuromuscular junction. Discusses the temporary nature of the effect and its relationship to symptom relief.

3. Botulinum Toxin Type A (BTX-A)

   Provides background on botulinum toxin types and discusses general product and treatment context. Covers broad considerations such as dosing, duration, and common clinical use.

4. Chemodenervation Candidates

   Describes the types of patients and neurologic or neuromuscular conditions discussed as potential candidates for treatment. Focuses on the clinical settings in which the procedure may be considered.

5. The Chemodenervation Procedure

   Outlines the procedural workflow at a high level, including muscle identification and treatment planning. References general methods used to localize target muscles and assess treatment response.

6. Coding Chemodenervation

   Summarizes the CPT coding framework discussed in the article and the anatomic categories addressed. Includes related reporting context for chemodenervation and associated procedure coding topics.

7. Clinical Examples

   Presents illustrative case scenarios showing how chemodenervation may be applied in different clinical settings. The examples demonstrate the range of anatomic regions and neurologic conditions discussed in the article.